Skip to main content

New GLP-1 Indications: What you need to know

Published Date

Given that obesity is strongly associated with many chronic conditions, it comes as no surprise that manufacturers are looking to treat these conditions by exploring new FDA indications for GLP-1s. Current conditions being studied range from chronic kidney disease, sleep apnea, and nonalcoholic steatohepatitis to conditions not commonly associated with obesity like Alzheimer's, addiction, substance abuse, and smoking cessation. Notably, the FDA approved a new indication for the use of Wegovy(R) to reduce the risk of serious cardiovascular events in patients with cardiovascular disease (CVD) & overweight or obesity in March 2024. 

While these research developments underscore the potential of GLP-1s treating diseases beyond diabetes and obesity, the emergence of new indications is not without its challenges -- particularly issues stemming from GLP-1 medication shortages, high costs, and potential hurdles in providing coverage.

Join Omada Health’s Chief Medical Officer, Carolyn Jasik, MD, and Clinical Pharmacist Ketan Patel, PharmD from Mercer as they share insights in how GLP-1 medications have expanded to treat additional chronic conditions, particularly CVD, and the questions that remain for how to integrate these treatments affordably and efficiently into care models. 

 

Specifically, this webinar covers the following: 

  • What are the new indications being studied?

  • What do additional indications mean for health outcomes and cost?

  • Will this expansion impact employer coverage?

  • When it comes to 2025 benefits planning, what should employers be thinking about or doing to prepare for expanded indications?  

  

Carolyn Jasik , MD

Chief Medical Officer, Omada Health

Carolyn is a board-certified physician with a career spanning health technology startups, multidisciplinary care, education, and research associateships. Carolyn previously spent 14 years with the University of California as an Associate Professor of Pediatrics and Clinical Instructor at San Francisco General Hospital. She completed her Medical Degree at the University of Chicago’s Pritzker School of Medicine and her research training at the University of California, San Francisco. At Omada, Carolyn supports the clinical and research teams to create and test the next generation of integrated chronic disease care programming via digital therapeutics.

Ketan Patel, PharmD

Clinical Pharmacist, Mercer 

Ketan is a registered pharmacist and clinical consultant at MercerWELL with nearly a decade of healthcare experience. He specializes in clinical solutions and strategy delivery, and serves as a subject matter expert in Mercer's Chronic Conditions vertical team, focusing on cardiometabolic care. Ketan holds a Doctor of Pharmacy (Pharm.D.) from Lake Erie College of Osteopathic Medicine and a Bachelor's in Biology from the University of South Carolina.